Non-Hodgkin Lymphome (NHL)

Multiples Myelom

  • HD7, Status: aktiv, NCT03617731

    A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma
  • Kurzinformation

 

Ansprechpartner:
Dr. Riechel 
Telefon: 0711 278 22504
E-Mail: C.Riechel@klinikum-stuttgart.de


Studienzentrale
Telefon: 0711 278-30410, -30411, -30414
E-Mail: scc-studienzentrale@klinikum-stuttgart.de